Shuimu BioSciences, founded with a mission to revolutionize drug discovery and therapeutic innovation, leverages cutting-edge cryo-electron microscopy (cryo-EM) and Artificial Intelligence (AI) technologies. The company aims to accelerate the development of novel therapeutics by providing one-stop solutions for structure-based drug discovery. Shuimu's offerings include advanced cryo-EM platforms, proprietary GraFuture technologies, and AI-driven data processing and modeling, targeting the pharmaceutical and biotech sectors.
Notable achievements include the publication of significant research such as the cryo-EM structure of DNA polymerase θ helicase domain in complex with inhibitor novobiocin. Shuimu's impact is marked by its eight 300kV cryo-EMs and its role in advancing precision medicine for challenging diseases. The company’s technological excellence and global leadership position it as a key partner in next-generation drug innovation.
